Last reviewed · How we verify
MSC2499550A
At a glance
| Generic name | MSC2499550A |
|---|---|
| Also known as | L-PZQ |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers (PHASE1)
- Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSC2499550A CI brief — competitive landscape report
- MSC2499550A updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI